Moreover, CD39 has also been reported as a useful marker to discriminate antigen-specific from nonspecific bystander CD8 + T cells in a tumour environment, providing an approach to identify tumour-reactive CD8 + T cells, with important implications for developing future therapeutic strategies [11–13]. This evidence concerns the gene CD8A and neoplasm.